<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31924240</article-id><article-id pub-id-type="pmc">6954510</article-id><article-id pub-id-type="publisher-id">2724</article-id><article-id pub-id-type="doi">10.1186/s13054-019-2724-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: some nuances</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7997-4294</contrib-id><name><surname>Aguilar</surname><given-names>Gerardo</given-names></name><address><email>gerardo.aguilar@uv.es</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ferriols</surname><given-names>Rafael</given-names></name><address><email>rafael.ferriols@uv.es</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez-Castro</surname><given-names>Sara</given-names></name><address><email>saradacuris@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ezquer</surname><given-names>Carlos</given-names></name><address><email>cezquer@incliva.es</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Pastor</surname><given-names>Ernesto</given-names></name><address><email>ernesto.pastormz@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Carbonell</surname><given-names>Jose A.</given-names></name><address><email>joseacarbonell19@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Al&#x000f3;s</surname><given-names>Manuel</given-names></name><address><email>manuel.alos@uv.es</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Navarro</surname><given-names>David</given-names></name><address><email>david.navarro@uv.es</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.411308.f</institution-id><institution>Critical Care Unit, Anesthesiology and Critical Care Department, </institution><institution>Hospital Cl&#x000ed;nico Universitario de Valencia, </institution></institution-wrap>Valencia, Spain </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.429003.c</institution-id><institution>INCLIVA Health Research Institute, </institution></institution-wrap>Avenida de Men&#x000e9;ndez y Pelayo, 4, 46010 Valencia, Spain </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2173 938X</institution-id><institution-id institution-id-type="GRID">grid.5338.d</institution-id><institution>School of Medicine, </institution><institution>University of Valencia, </institution></institution-wrap>Avenida Blasco Ib&#x000e1;&#x000f1;ez, 15, 46010 Valencia, Spain </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.411308.f</institution-id><institution>Department of Pharmacy, </institution><institution>Hospital Cl&#x000ed;nico Universitario de Valencia, </institution></institution-wrap>Avenida Blasco Ib&#x000e1;&#x000f1;ez, 17, 46010 Valencia, Spain </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.411308.f</institution-id><institution>Department of Microbiology, </institution><institution>Hospital Cl&#x000ed;nico Universitario de Valencia, </institution></institution-wrap>Avenida Blasco Ib&#x000e1;&#x000f1;ez, 17, 46010 Valencia, Spain </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>24</volume><elocation-id>11</elocation-id><history><date date-type="received"><day>22</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par8">We have read the recent letter by Honore et al. [<xref ref-type="bibr" rid="CR1">1</xref>] about our findings published in this journal regarding the influence of continuous renal replacement therapy (CRRT) on the pharmacokinetics of ceftolozane-tazobactam (C/T) [<xref ref-type="bibr" rid="CR2">2</xref>]. In our report, we decided to administer a 3&#x02009;g/iv dose every 8&#x02009;h taking into account two previous studies referenced in our paper [<xref ref-type="bibr" rid="CR2">2</xref>] and another one which showed CRRT to be an independent predictor of clinical failure (OR 4.5, 95% CI 1.18&#x02013;17.39, <italic>p</italic>&#x000a0;=&#x02009;0.02) when C/T is administered at 1.5&#x02009;g every 8&#x02009;h [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par9">As Honore et al. explain in their paper, the C/T eliminitation was assumed by hemodiafiltration and the adsorption was not assessed [<xref ref-type="bibr" rid="CR1">1</xref>]. However, there is a misunderstanding in this letter [<xref ref-type="bibr" rid="CR1">1</xref>], because we used a polysulphone membrane (Fresenius, Germany) instead of an acrylonitrile 69 Multiflow (AN-69-M). In contrast to highly adsorptive membranes (HAM; e.g., AN69 surface-treated, AN69-ST), the antibiotic adsorption with polysulphone ones is negligible, which facilitates antibiotic adaptation during CRRT [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par10">Our data should not be extrapolated to other clinical scenarios, as noted by Honore et al. [<xref ref-type="bibr" rid="CR1">1</xref>]. In our report, ceftolozane and tazobactam plasma concentrations remained above the minimal inhibitory concentration (MIC), for MICs of up to 8&#x02009;&#x003bc;g/mL, but we estimated that the administration of standard doses of 1&#x02009;g/0.5&#x02009;g, even with polysulphone membranes, could compromise the effectiveness of C/T for not reaching adequate tazobactam concentrations. Thus, the use of HAM would represent a real risk factor of clinical failure when a C/T dose of 1.5&#x02009;g every 8&#x02009;h is administered, especially in multidrug-resistant infections [<xref ref-type="bibr" rid="CR3">3</xref>]. Therefore, we agree with Honore et al. [<xref ref-type="bibr" rid="CR1">1</xref>] that therapeutic drug monitoring (TDM) is critical when using C/T for patients receiving CRRT, especially when MICs of bacteria like multidrug-resistant (MDR) <italic>Pseudomonas aeruginosa</italic> are considered very high. However, the recommendation of continuous (over 24&#x02009;h) vs extended (over 2 to 4&#x02009;h) or intermittent (over 30 to 60&#x02009;min) infusion of beta-lactams is still under debate [<xref ref-type="bibr" rid="CR5">5</xref>].</p></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AN-69-M</term><def><p id="Par1">Acrylonitrile 69 Multiflow</p></def></def-item><def-item><term>AN-69-ST</term><def><p id="Par2">AN69-surface treated</p></def></def-item><def-item><term>C/T</term><def><p id="Par3">Ceftolozane-tazobactam</p></def></def-item><def-item><term>CRRT</term><def><p id="Par4">Continuous renal replacement therapy</p></def></def-item><def-item><term>HAM</term><def><p id="Par5">Highly adsorptive membranes</p></def></def-item><def-item><term>MDR</term><def><p id="Par6">Multidrug-resistant</p></def></def-item><def-item><term>MIC</term><def><p id="Par7">Minimal inhibitory concentration</p></def></def-item></def-list></glossary><fn-group><fn><p>This reply refers to the comment available at: 10.1186/s13054-019-2692-2.</p></fn><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>GA, RF, and DN designed the paper. All authors participated in drafting and reviewing the manuscript. All authors read and approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par11">Not applicable.</p></notes><notes><title>Consent for publication</title><p id="Par12">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par13">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honore</surname><given-names>PM</given-names></name><name><surname>Mugisha</surname><given-names>A</given-names></name><name><surname>Gutierrez</surname><given-names>LB</given-names></name><name><surname>Redant</surname><given-names>S</given-names></name><name><surname>Kaefer</surname><given-names>K</given-names></name><name><surname>Gallerani</surname><given-names>A</given-names></name><name><surname>De Bels</surname><given-names>D</given-names></name></person-group><article-title>Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: additional insights</article-title><source>Crit Care</source><year>2019</year><volume>23</volume><issue>1</issue><fpage>406</fpage><pub-id pub-id-type="doi">10.1186/s13054-019-2692-2</pub-id><pub-id pub-id-type="pmid">31831032</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>G</given-names></name><name><surname>Ferriols</surname><given-names>R</given-names></name><name><surname>Mart&#x000ed;nez-Castro</surname><given-names>S</given-names></name><name><surname>Ezquer</surname><given-names>C</given-names></name><name><surname>Pastor</surname><given-names>E</given-names></name><name><surname>Carbonell</surname><given-names>JA</given-names></name><name><surname>Al&#x000f3;s</surname><given-names>M</given-names></name><name><surname>Navarro</surname><given-names>D</given-names></name></person-group><article-title>Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration</article-title><source>Crit Care.</source><year>2019</year><volume>23</volume><issue>1</issue><fpage>145</fpage><pub-id pub-id-type="doi">10.1186/s13054-019-2434-5</pub-id><pub-id pub-id-type="pmid">31027499</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>Castaldo</surname><given-names>N</given-names></name><name><surname>Cattelan</surname><given-names>A</given-names></name><name><surname>Mussini</surname><given-names>C</given-names></name><name><surname>Righi</surname><given-names>E</given-names></name><name><surname>Tascini</surname><given-names>C</given-names></name><etal/></person-group><article-title>Ceftolozane/tazobactam for the treatment of serious <italic>P. aeruginosa</italic> infections: a multicenter nationwide clinical experience</article-title><source>Int J Antimicrob Agents.</source><year>2019</year><volume>53</volume><issue>4</issue><fpage>408</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.11.001</pub-id><pub-id pub-id-type="pmid">30415002</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honore</surname><given-names>PM</given-names></name><name><surname>Spapen</surname><given-names>HD</given-names></name></person-group><article-title>What a clinician should know about a renal replacement membrane?</article-title><source>J Transl Intern Med</source><year>2018</year><volume>6</volume><fpage>62</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.2478/jtim-2018-0016</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YR</given-names></name><name><surname>Miller</surname><given-names>PD</given-names></name><name><surname>Alzghari</surname><given-names>SK</given-names></name><name><surname>Blanco</surname><given-names>DD</given-names></name><name><surname>Hager</surname><given-names>JD</given-names></name><name><surname>Kuntz</surname><given-names>KS</given-names></name></person-group><article-title>Continuous infusion versus intermittent bolus of beta-lactams in critically ill patients with respiratory infections: a systematic review and meta-analysis</article-title><source>Eur J Drug Metab Pharmacokinet</source><year>2018</year><volume>43</volume><issue>2</issue><fpage>155</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1007/s13318-017-0439-5</pub-id><pub-id pub-id-type="pmid">29027128</pub-id></element-citation></ref></ref-list></back></article>